Documentation Required for CPAP Usage
For Medicare and most insurance reimbursement, you must document: (1) objective polysomnography confirming OSA diagnosis with specific AHI thresholds, (2) face-to-face clinical reevaluation between days 31-91 showing symptom improvement, and (3) objective adherence data demonstrating CPAP use ≥4 hours/night on 70% of nights during any consecutive 30-day period within the first 3 months. 1
Initial Diagnostic Documentation
Polysomnography (PSG) is mandatory for CPAP reimbursement by CMS and most insurers. 2 The diagnostic sleep study must include:
- Comprehensive PSG measurements: oxygen saturation, rib cage and abdominal movement, nasal and oral airflow, snoring sounds, electroencephalography, electrooculography, electromyography, electrocardiogram, and leg electromyogram to document periodic leg movements 2
- Apnea-Hypopnea Index (AHI) documentation: CMS covers treatment when AHI >15, or when AHI >5 with comorbidities such as excessive daytime sleepiness, hypertension, or cardiovascular disease 2
- CPAP titration data: PSG is typically followed by continuous positive airway pressure titration to determine therapeutic pressure 2
Important caveat: If CPAP was initially prescribed based on portable monitoring and the patient subsequently fails the 90-day adherence criteria, CMS mandates an in-laboratory polysomnogram, though the validity of this requirement is questionable in patients with unequivocal severe OSA on portable studies 1
Pre-Treatment Clinical Documentation
Document the following clinical elements in the medical record:
- Cardinal OSA symptoms: excessive daytime sleepiness (EDS), snoring, witnessed apneas, nocturia, cognitive impairment 2
- Epworth Sleepiness Scale (ESS): useful for documenting baseline daytime drowsiness, though not validated in older adults 2
- Physical examination findings: upper airway assessment (nasal and pharyngeal), skeletal facial structure (retrognathia/micrognathia), neck collar size (>17 inches in men, >16 inches in women), obesity assessment 2
- Comorbidities: hypertension (especially treatment-resistant), heart disease, hypothyroidism, stroke, diabetes 2, 1
- Medication review: sedative-hypnotics, opiate analgesics, alcohol use—all can contribute to breathing difficulties or daytime sleepiness 2
Adherence Monitoring Documentation (Days 31-91)
CMS requires specific adherence documentation between Day 31 and Day 91 after initiating therapy for continued reimbursement beyond 12 weeks. 1 This includes:
Objective CPAP Usage Data
Download and document from the CPAP device's tracking system:
- Total nights CPAP was used vs. not used 1
- Percentage of nights with usage >4 hours/night 1
- Average usage on nights when CPAP was used 1
- Average usage on all nights 1
The adherence threshold: CPAP use ≥4 hours/night on 70% of nights during any consecutive 30-day period within the first 3 months 1
Face-to-Face Clinical Reevaluation
The treating physician must conduct and document a face-to-face visit (not just review of downloaded data) showing: 1
- Symptom improvement: documented reduction in OSA symptoms such as daytime sleepiness (ESS), nocturia, headaches, sleep fragmentation, or insomnia 1
- Quality of life improvement: using validated instruments like FOSQ, SF-36, or SAQLI 1
- Comorbidity improvement: blood pressure reduction, improved diabetic control, reduced cardiovascular symptoms 1
Additional Technical Parameters to Document
While not always required for basic reimbursement, document these parameters to demonstrate therapeutic effectiveness:
- Residual AHI on CPAP: event detection from device tracking systems 1
- Mask leak data: excessive leak compromises effectiveness; thresholds vary by manufacturer (ResMed: >24 L/min nasal, >36 L/min full-face; Fisher & Paykel: >60 L/min; DeVilbiss: >95 L/min) 1, 3
- Pressure settings: document therapeutic pressure level 2
Critical Timing Considerations
The American Thoracic Society recommends earlier adherence assessment (7-90 days rather than waiting until day 31) because addressing CPAP intolerance early improves long-term adherence. 1 However, CMS reimbursement rules mandate the 31-91 day window for formal documentation. 1
Early follow-up within 2 weeks of CPAP initiation is recommended by the American Academy of Sleep Medicine to optimize adherence, though this is separate from the formal CMS documentation requirement. 4
Common Documentation Pitfalls
- Waiting too long to address problems: CPAP adherence patterns are typically established early in treatment; delaying intervention until day 31 may allow problems to become entrenched 1
- Relying solely on objective data without clinical assessment: CMS requires both objective adherence data AND documented clinical benefit from a face-to-face evaluation 1
- Missing the 31-91 day window: documentation outside this timeframe may not satisfy CMS requirements for continued coverage 1
- Inadequate baseline symptom documentation: without clear baseline symptoms documented, demonstrating improvement becomes difficult 2
Ongoing Long-Term Documentation
OSA should be treated as a chronic disease requiring longitudinal monitoring. 1 Continue documenting:
- Periodic adherence downloads: monitor CPAP usage long-term, not just during the initial 90 days 1
- Clinical outcomes: ongoing assessment of symptoms, comorbidities, and quality of life 1
- Side effects and interventions: document mask discomfort, nasal symptoms, pressure intolerance, and management strategies 4, 5